Menu
ncarol.com
  • Home
  • Books
  • Book Release
  • Technology
  • Music
  • Business
  • Education
  • Health
  • Financial
ncarol.com

Baebies Announces FDA Acknowledgement of Emergency Use Notification for FINDER 1.5 Instrument and FINDER SARS-CoV-2 Test – RT-PCR within 17 Minutes
ncarol.com/10109576

Trending...
  • UK Financial Ltd Executes 100% Success Rate on All ERC-3643 Transfers to Coin Holders of MayaCat Regulated Security Token and Maya Preferred PRA
  • Sobreseimiento de Nicolás dos Santos y Jorge Méndez expone demandas millonarias a Paraguay y boicot a la Hidrovía
  • Color Card Administrator Highlights Growing Enterprise Demand for Operational Infrastructure in Business Card Identity Governance
DURHAM, N.C.--(BUSINESS WIRE)--Baebies, a growth-stage company developing innovative products to enable early disease detection and comprehensive diagnosis, today announced that the U.S. Food & Drug Administration (FDA) acknowledged the company's Emergency Use Notification (EUN) for an RT-PCR test to detect SARS-CoV-2 on the FINDER® 1.5 Instrument. The company's FINDER SARS‑CoV-2 Test is intended for the qualitative detection of RNA from the SARS-CoV-2 virus in nasopharyngeal and nasal swab specimens with RT-PCR performed within 17 minutes.

"Our FINDER SARS-CoV-2 test combines the accuracy of RT-PCR testing with a rapid turn-around time, which is made possible by our innovative digital microfluidics technology," says Richard West, Co‑Founder and Chief Executive Officer of Baebies. "We are launching the FINDER 1.5 Instrument and FINDER SARS-CoV-2 Test to address the continued need for access to fast and accurate testing in health care facilities with high complexity laboratories. Our team has worked tirelessly for the last year to bring this to market and we are very excited to reach this important milestone."

The FINDER 1.5 platform includes a toaster-sized instrument and disposable single-use cartridge and features:
  • Small footprint at just 8 inches wide with a commercial tablet interface
  • Easy and intuitive workflow
  • Quick installation and no specialized training needed
  • Digital microfluidic technology, which minimizes sample and reagent volumes

Development of the FINDER SARS-CoV-2 Test was supported in part by funds from the National Institutes of Health's Rapid Acceleration of Diagnostics (RADx) initiative. The underlying digital microfluidics (DMF) technology is a method to programmably manipulate tiny droplets of liquid by electrical control of surface tension on a disposable cartridge. Baebies' DMF technology is protected by several hundred patents.

More on ncarol.com
  • Adherix Health launches SMS-first retention platform for GLP-1 treatment programs
  • Kryptokasinot.io Raises Concerns Over Proposed Cryptocurrency Restrictions in Finland's Gambling Reform
  • New Home of the Month: Spacious Luxury Meets Modern Design in The Bristol at Heritage at Manalapan
  • The Calida Group Announces Sale of Ely at Fort Apache for $57.5 Million
  • Bat Cave Flooding Reopens Hurricane Helene Trauma

Digital microfluidics supports multifunctional assay methods – including molecular, immunoassay, and chemistry – on the same cartridge. Currently under FDA 510(k) review, FINDER tests for glucose-6-phosphate dehydrogenase (G6PD) deficiency, a genetic defect leading to anemia and severe jaundice. FINDER can efficiently test for G6PD deficiency from low blood volume (50 µL) with a turn-around time of approximately 15 minutes after sample introduction. Additionally, Baebies has a robust development pipeline and recently won the prestigious 2020 AACC Disruptive Technology Award for FINDER in a tight competition emerging as the next innovative testing solution that will transform patient care.

"In development of our FINDER SARS-CoV-2 Test, we focused on accelerating RT-PCR and sample processing for rapid results through several innovations – all made possible by digital microfluidics," noted Vamsee Pamula, co-founder and President. "This technology powers both our diagnostic platform, FINDER, and FDA-authorized newborn screening platform, SEEKER. Baebies' core focus still remains neonatal and pediatric diagnostics, however, the current COVID-19 pandemic doesn't distinguish between children and adults – everyone is at risk."

More on ncarol.com
  • Summer Festivals in Gunma Prefecture: Song, Dance, and Vibrant Color – Get There Via Tobu Railway!
  • Jetperch Introduces Joulescope JS320 Precision Energy Analyzer for Low-Power Embedded System Development
  • AI-Powered Trading Bots Are Transforming Forex, Gold, and Digital Markets as DefiHash Expands Intelligent Quantitative Infrastructure
  • Early Bird Registration Open for FLYING HY, the Top Hydrogen and Battery Electric Aviation Event
  • Century Fasteners Corp. Hires Tony Marano as Director of Human Resources

About Baebies

Baebies - guided by the vision that "everyone deserves a healthy start" - develops and commercializes products and services that enable early disease detection and comprehensive diagnosis. Baebies has shipped over 10 million tests. Baebies' products include SEEKER®, an FDA-authorized and CE-marked high throughput newborn screening platform, and FINDER®, a CE-marked flexible, single sample testing platform that is currently not commercially available in the U.S. The FINDER 1.5 Instrument and FINDER SARS-CoV-2 Test have been validated but FDA's independent review of this validation is pending. Our mission is to save lives and make lives better for all by bringing new technologies, new tests and new hope to children, parents and healthcare professionals worldwide. Baebies is headquartered in Durham, North Carolina. For more information, visit baebies.com and follow on LinkedIn, Twitter and YouTube.
Filed Under: Business

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on ncarol.com
  • Medical Experts Highlight the Importance of Second Opinions in Death Investigations
  • Joseph Nybyk aka Neibich of Gilbert, Arizona
  • Omnitronics Unveils 100% Software omniGateDMR and omniGateP25 RoIP Gateways
  • KRE PRIME Launches Adaptive Convertible Jumpsuit
  • USA Med Bed Helping Home Care Patients with Refurbished Hill Rom Hospital Beds
  • Sobreseimiento de Nicolás dos Santos y Jorge Méndez expone demandas millonarias a Paraguay y boicot a la Hidrovía
  • CAPHRA warns Southeast Asia not to repeat Australia's nicotine policy failure
  • Milo3D.ai Launches Free AI 3D Model Generator That Turns Text and Images Into Game-Ready 3D Assets in Seconds
  • UK Financial Ltd Executes 100% Success Rate on All ERC-3643 Transfers to Coin Holders of MayaCat Regulated Security Token and Maya Preferred PRA
  • Blank Space: The Unofficial Taylor Swift Tribute Brings Eras Tour Magic To Cities Across America
  • Love Must Be the Guide: Live Good Shares a Message of Humanity, Compassion and Hope
  • D.R. Crotzer Announces A New Science Fiction Book Series Exploring Life Energy, Dreams, and the Mystery of Existence
  • Color Card Administrator Highlights Growing Enterprise Demand for Operational Infrastructure in Business Card Identity Governance
  • American Properties Celebrates Grand Opening and Ribbon Cutting Ceremony at Heritage at South
  • Crosswalk Ministries USA Announces 2026 Child and Family Well-Being Conference in Stockbridge, Georgia
  • Research reveals "The Borderless Pay Standard," a 48-point gap between multinational employers and workers on transparent pay expectations
  • Global.ai Appoints Freedomtech Solutions as Specialist Partner for Agentic AI
  • ASCLD Honors Jeremy Triplett with 2026 Briggs J. White Award
  • BarnOps Launches Equine Facility Management Software with GPS Staff Tracking and Weather Alerts
  • Lansdowne Photographer Steven Weisz Selected for Philadelphia City Hall Exhibition
_catLbl0 _catLbl1

Popular on ncarol.com

  • Altruvest and Financial Executives International Canada Announce Strategic Partnership to Strengthen Nonprofit Boards Across Canada - 117
  • Virginia Moving Company Nearly Doubles Customer Calls in Two Weeks After Switching to CARL — the Bold New Alternative to WordPress - 115
  • RAS AP Consulting Advances to RFP Stage in Heidelberg Materials' SAP Vendor & Customer Master Data Modernization Initiative - 103
  • 5,521 College Athletes Launch Own Merch Stores in Just 30 Days on AthleteMerch.com, Reaching 7,975 Live Storefronts Nationwide
  • CCHR Report Links 145 Violent Incidents to Psychiatric Drug Exposure, Urges National Oversight and Action
  • UK Financial Ltd Executes 100% Success Rate on All ERC-3643 Transfers to Coin Holders of MayaCat Regulated Security Token and Maya Preferred PRA
  • T. Jones Group's Cameron Jones Serves as Judge for the 2026 CHBA National Awards for Housing Excellence
  • $10 Million Annual Revenue Merger, Profitable Partner in AI Powered Specialty Automotive Sales Projected to Scale Above $200M: Stock Symbol: NWPG
  • $29.8 Million Record Setting Q1 with Boosted Annual Guidance to $160 Million for Expanding Pre-Owned Boat Dealer: Off The Hook YS, Inc. N Y S E: OTH
  • A Hidden Magical World Awaits in Ashley Gayheart's Upcoming Young Adult Fantasy, Rosewood Academy: The Awakening

Similar on ncarol.com

  • Milton Collier, CEO & President of Freight Broker 911, Eliminates the #1 Barrier to Entry in Logistics: Announces 100% Free Freight Broker Training
  • FDA-Cleared AI Neuropsychiatry Platform, Million-Dose Ketamine Manufacturing and Presidential Psychedelic Initiative Drive Growing Momentum for NRXP
  • Accelerating Toward Commercialization as FDA Momentum, AI Neurotherapy & Manufacturing Expansion Drive Multi-Catalyst Growth Story; N A S D A Q: NRXP
  • A Groundbreaking New Book Challenging the Role of Social Media in Small Business Marketing
  • 50 Million Years of Leadership Wisdom, Now in a Field Guide
  • KRE PRIME Launches Adaptive Convertible Jumpsuit
  • Sobreseimiento de Nicolás dos Santos y Jorge Méndez expone demandas millonarias a Paraguay y boicot a la Hidrovía
  • UK Financial Ltd Executes 100% Success Rate on All ERC-3643 Transfers to Coin Holders of MayaCat Regulated Security Token and Maya Preferred PRA
  • Global.ai Appoints Freedomtech Solutions as Specialist Partner for Agentic AI
  • Triple-Digit Growth, OTCQX Market Upgrade and a Rapidly Expanding Specialty Healthcare Platform: Cardiff Lexington Corporation: Stock Symbol: CDIX
Copyright © 2026 ncarol.com | Contact Us | Privacy Policy | Terms of Service | Contribute